Advertisement

Durchblutungsfördernde Mittel

  • Ulrich Schwabe

Zusammenfassung

Die Verordnungen durchblutungsfördernder Arzneimittel sind seit 1992 rückläufig. Auch 2003 hat das Verordnungsvolumen (−11%) weiter abgenommen, Hauptursache ist die fragliche Wirksamkeit der Vasodilatatoren, die eine Anwendung nach den aktuellen Therapieempfehlungen nicht mehr rechtfertigen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Antithrombotic Trialists’ Collaboration (2002): Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 324: 71–86.CrossRefGoogle Scholar
  2. Arzneimittelkommission der Deutschen Apotheker (1995): Naftidrofuryl Infusionslösung. Pharmazeut Ztg 140: 2222.Google Scholar
  3. Barradell LB, Brogden RN (1996): Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging 8: 299–322.PubMedCrossRefGoogle Scholar
  4. Boccalon H, Lehert P, Mosnier M (2001): Effect of naftidrofuryl on physiological Walking distance in patients with intermittent claudication. Ann Cardiol Angeiol 50: 175–182.CrossRefGoogle Scholar
  5. Böhme H, Brülsaver M, Härtel U, Bollinger A (1987): Kontrollierte Studie zur Wirksamkeit von I.A. PGE, Infusionen bei peripherer arterieller Verschlußkrankheit im Stadium III und IV. Vasa 20(Suppl): 206–208.Google Scholar
  6. Burns P, Gough S, Bradbury AW (2003): Management of peripheral arterial disease in primary care. Brit Med J 326: 584–588.PubMedCrossRefGoogle Scholar
  7. De Backer TL, Van der Stichele RH, Warie HH, Bogaert MG (2000): Oral vasoactive medication in intermittent claudication: utile or futile? Eur J Clin Pharmacol 56: 199–206.PubMedCrossRefGoogle Scholar
  8. Diehm C, Hübschmüller C, Stamller F (1988): Intravenöse Prostaglandin El-Therapie bei Patienten mit peripherer arterieller Verschlußkrankheit (AVK) im Stadium III: Eine doppelblinde, Placebokontrollierte Studie. In: Heinrich H, Böhme H, Rogatti W (Hrsg): Prostaglandin El-Wirkungen und therapeutische Wirksamkeit. Springer-Verlag, Heidelberg, S. 133–143.Google Scholar
  9. Dormandy JA, Rutherford RB (2000): Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 31:Sl–S296.Google Scholar
  10. Drabæk H, Petersen JR, Winberg N, Hansen KF, Mehlsen J (1996): The effect of Ginkgo biloba extract in patients with intermittent claudication. Ugeskr Laeger 158:3928–3931.PubMedGoogle Scholar
  11. Ernst E (1994): Pentoxifylline for intermittent claudication. A critical review. Angiology 45: 339–345.Google Scholar
  12. Girolami B, Bernardi E, Prins MH, Wouter ten Cate J, Hettiarachchi R et al. (1999): Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl. Arch Intern Med 159: 337–345.PubMedCrossRefGoogle Scholar
  13. Haberkamp TJ, Tanyeri HM (1999): Management of idiopathic sudden sensorineural hearing loss. Am J Otol 20: 587–592.PubMedGoogle Scholar
  14. Hiatt WR (2001): Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344:1608–1621.PubMedCrossRefGoogle Scholar
  15. Hiatt WR (2002): Pharmacological therapy for peripheral arterial disease and claudication. J Vasc Surg 36: 1283–1291.PubMedCrossRefGoogle Scholar
  16. Housley E (1988): Treating claudication in five words. Brit Med J 296:1483–1484.CrossRefGoogle Scholar
  17. Leng GC, Fowler B, Ernst E (2000): Exercise for intermittent claudication. Cochrane Database Syst Rev (2): CD000990.Google Scholar
  18. Pedersen TR, Kjekshus J, Pyörälä K, Olsson AG, Cook TJ et al. (1998): Effect of Simvastatin on ischemic signs and Symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 81: 333–335.PubMedCrossRefGoogle Scholar
  19. Probst R, Tschopp K, Ludin E, Kellerhals B, Podvinec M, Pfaltz CR (1992): A randomized, double-blind, placebo-controlled study of dextran/pentoxifylline medication in acute acoustic trauma and sudden hearing loss. Acta Otolaryngol 112:435–443.PubMedCrossRefGoogle Scholar
  20. Radack K, Wyderski RJ (1990): Conservative management of intermittent claudication. Ann Intern Med 113:135–146.PubMedGoogle Scholar
  21. Reisser C, Weidauer H (2001): Ginkgo biloba extract Egb 761® or pentoxifylline for the treatment of sudden deafness: a randomized, reference-controlled, double-blind study. Acta Otolaryngol 121: 579–584.PubMedCrossRefGoogle Scholar
  22. Reiter M, Bucek RA, Stumpflen A, Minar E (2004): Prostanoids for intermittent claudication. Cochrane Database Syst Rev 2004(1): CD000986.Google Scholar
  23. Sakaguchi S (1984): Prostaglandin E1 intra-arterial infusion therapy in patients with ischemic ulcer of the extremities. Int Angiol 3: 39–42.Google Scholar
  24. Schoop W, Breddin K, Diehm C, Gruß J, Held K et al. (1996): Klinische Prüfung mit Ginkgo biloba-Spezialextrakt Egb 761 bei Patienten mit peripherer arterieller Verschlußkrankheit im Stadium II b nach Fontaine im Vergleich zu Placebo. Posterpublikation, Jahreskongress der Schweizerischen Gesellschaft für Angiologie 1.–2.11.1996.Google Scholar
  25. The Ciprostene Study Group (1991): The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. J Clin Pharmacol 31:81–87.Google Scholar
  26. The ICAI Study Group (1999): Prostanoids for chronic critical leg ischaemia: a randomized, controlled, open-label trial with Prostaglandin El. Ann Intern Med 130:412–421.Google Scholar
  27. Transparenzkommission (1983): Transparenzliste für das Teilgebiet periphere arterielle Durchblutungsstörungen. Bundesanzeiger Nr. 169 vom 9.9.1983.Google Scholar
  28. Trübestein G, Diehm C, Gruss JD, Horsch S (1987): Prostaglandin El in chronic arterial disease: a multicentre study. Vasa 17(Suppl): 39–43.PubMedGoogle Scholar
  29. Trübestein G, von Bary S, Breddin K, Diehm C, Gruss JD, Heinrich H et al. (1989): Intravenous Prostaglandin El versus pentoxifylline therapy in chronic arterial occlusive disease: a controlled randomised multicenter study. Vasa 28(Suppl): 44–49.PubMedGoogle Scholar
  30. Walker GA, MacMannaford JC (1995): A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. Fundam Clin Pharmacol 9:387–394.PubMedCrossRefGoogle Scholar
  31. Weinaug P (1984): Die Spontanremission beim Hörsturz. HNO 32: 346–351.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Ulrich Schwabe
    • 1
  1. 1.Pharmakologisches Institut der Universität HeidelbergHeidelberg

Personalised recommendations